Relationship between P-glycoprotein and second-generation antipsychotics

Pharmacogenomics

Volumn 12, Issue 8, 2011, Pages 1193-1211

  Moons, Tim ^a   De Roo, Mariska ^b   Claes, Stephan ^a   Dom, Geert ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Centres for Mental Health Care   (Netherlands)

^c Psychiatric Centre Alexian Brothers   (Belgium)

Author keywords

ABCB1; C1236T; C3435T; G2677T; MDR1; p glycoprotein; P gp; SGA

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PEROSPIRONE; RISPERIDONE; SECOND GENERATION ANTIPSYCHOTIC AGENT; UNCLASSIFIED DRUG;

ABCB1 GENE; AKATHISIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPSYCHOTIC ACTIVITY; AREA UNDER THE CURVE; BINDING AFFINITY; BRAIN LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TARGETING; DRUG UPTAKE; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; KNOCKOUT GENE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PROLACTIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP3A; HUMANS; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

ANIMALIA;

EID: 80051773262     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.55     Document Type: Review

References (111)

1. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, 'just the facts' 5. Treatment and prevention. Past, present, and future. Schizophr. Res. 122(1-3), 1-23 (2010).
2. Sharom FJ, Lugo MR, Eckford PD. New insights into the drug binding, transport and lipid flippase activities of the P-glycoprotein multidrug transporter. J. Bioenerg. Biomembr. 37(6), 481-487 (2005). (Pubitemid 43725180)
3. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. USA 84(21), 7735-7738 (1987).
4. Ceckova-Novotna M, Pavek P, Staud F. P-glycoprotein in the placenta. expression, localization, regulation and function. Reprod. Toxicol. 22(3), 400-410 (2006).
5. Thorisson GA, Smith AV, Krishnan L, Stein LD. The International HapMap Project Website. Genome Res. 15(11), 1592-1593 (2005).
6. Sipeky C, Csongei V, Jaromi L et al. Genetic variability and haplotype profile of MDR1 (ABCB1) gene in Roma and Hungarian population samples with a review of the literature. Drug Metab. Pharmacokinet. 26(2), 206-215 (2011).
7. Tang K, Wong LP, Lee EJ, Chong SS, Lee CG. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum. Mol. Genet. 13(8), 783-797 (2004). (Pubitemid 38515208)
8. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97(7), 3473-3478 (2000). (Pubitemid 30183327)
9. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 62(1), 1-6 (2002). (Pubitemid 34680509)
10. Morita N, Yasumori T, Nakayama K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem. Pharmacol. 65(11), 1843-1852 (2003). (Pubitemid 36629509)
11. Salama NN, Yang Z, Bui T, Ho RJ. MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J. Pharm. Sci. 95(10), 2293-2308 (2006). (Pubitemid 44568538)
12. Kimchi-Sarfaty C, Oh JM, Kim IW et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811), 525-528 (2007). (Pubitemid 46175758)
13. Gow JM, Hodges LM, Chinn LW, Kroetz DL. Substrate-dependent effects of human ABCB1 coding polymorphisms. J. Pharmacol. Exp. Ther. 325(2), 435-442 (2008). (Pubitemid 351574805)
14. Hitzl M, Schaeffeler E, Hocher B et al. Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics 14(5), 309-318 (2004). (Pubitemid 38638918)
15. Haenisch S, Zimmermann U, Dazert E et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogen. J. 7(1), 56-65 (2007). (Pubitemid 46322080)
16. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C
17. Mosyagin I, Runge U, Schroeder HW et al. Association of ABCB1 genetic variants 3435CT to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. Epilepsia 49(9), 1555-1561 (2008).
18. Hitzl M, Drescher S, van der Kuip H et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11(4), 293-298 (2001). (Pubitemid 32537402)
19. Fellay J, Marzolini C, Meaden ER et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359(9300), 30-36 (2002). (Pubitemid 34119193)
20. Drescher S, Schaeffeler E, Hitzl M et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. 53(5), 526-534 (2002). (Pubitemid 34527155)
21. Kroetz DL, Pauli-Magnus C, Hodges LM et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13(8), 481-494 (2003). (Pubitemid 37034590)
22. Oselin K, Nowakowski-Gashaw I, Mrozikiewicz PM, Wolbergs D, Pahkla R, Roots I. Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene. Eur. J. Clin. Invest. 33(3), 261-267 (2003). (Pubitemid 36411546)
23. Meissner K, Jedlitschky G, Meyer Zu SH et al. Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 14(6), 381-385 (2004). (Pubitemid 38813692)
24. Owen A, Goldring C, Morgan P, Chadwick D, Park BK, Pirmohamed M. Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br. J. Clin. Pharmacol. 59(3), 365-370 (2005). (Pubitemid 40388091)
25. Simon C, Stieger B, Kullak-Ublick GA et al. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta. Neurol. Scand. 115(4), 232-242 (2007). (Pubitemid 46449584)
26. de Iudicibus S, de Pellegrin A, Stocco G, Bartoli F, Bussani R, Decorti G. ABCB1 gene polymorphisms and expression of P-glycoprotein and long-term prognosis in colorectal cancer. Anticancer Res. 28(6B), 3921-3928 (2008).
27. Tanabe M, Ieiri I, Nagata N et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 297(3), 1137-1143 (2001). (Pubitemid 32472514)
28. Goto M, Masuda S, Saito H et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than P-gp in recipients of living-donor liver transplantation. Pharmacogenetics 12(6), 451-457 (2002). (Pubitemid 34913527)
29. Moriya Y, Nakamura T, Horinouchi M et al. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull. 25(10), 1356-1359 (2002). (Pubitemid 39663201)
30. Nakamura T, Sakaeda T, Horinouchi M et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin. Pharmacol. Ther. 71(4), 297-303 (2002). (Pubitemid 34311459)
31. Nishioka C, Sakaeda T, Nakamura T et al. MDR1, MRP1 and MRP2 genotypes and in vitro chemosensitivity in Japanese patients with colorectal adenocarcinomas. Kobe. J. Med. Sci. 50(5-6), 181-188 (2004). (Pubitemid 41283764)
32. Uwai Y, Masuda S, Goto M et al. Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients. J. Hum. Genet. 49(1), 40-45 (2004). (Pubitemid 38186124)
33. Taheri M, Mahjoubi F, Omranipour R. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. Genet. Mol. Res. 9(1), 34-40 (2010).
34. Song P, Lamba JK, Zhang L et al. G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J. Clin. Pharmacol. 46(3), 373-379 (2006). (Pubitemid 43260324)
35. Chowbay B, Li H, David M, Cheung YB, Lee EJ. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br. J. Clin. Pharmacol. 60(2), 159-171 (2005). (Pubitemid 41075901)
36. van den Heuvel-Eibrink MM, Wiemer EA, de Boevere MJ et al. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood 97(11), 3605-3611 (2001).
37. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and P-gp expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogen. J. 7(3), 154-179 (2007). (Pubitemid 46794925)
38. Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin. Pharmacokinet. 38(5), 393-414 (2000). (Pubitemid 30265260)
39. Sheehan JJ, Sliwa JK, Amatniek JC, Grinspan A, Canuso CM. Atypical antipsychotic metabolism and excretion. Curr. Drug Metab. 11(6), 516-525 (2010).
40. Ring BJ, Catlow J, Lindsay TJ et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J. Pharmacol. Exp. Ther. 276(2), 658-666 (1996). (Pubitemid 126660505)
41. Lamba J, Strom S, Venkataramanan R et al. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin. Pharmacol. Ther. 79(4), 325-338 (2006).
42. Hosohata K, Masuda S, Yonezawa A et al. MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients. Pharm. Res. 26(7), 1590-1595 (2009).
43. Balle T, Halldin C, Andersen L et al. New a(1)-adrenoceptor antagonists derived from the antipsychotic sertindole-carbon-11 labelling and PET examination of brain uptake in the cynomolgus monkey. Nucl. Med. Biol. 31(3), 327-336 (2004). (Pubitemid 38353028)
44. Bozina N, Jovanovic N, Lovric M, Medved V. Clinical significance of a CYP2D6 poor metabolizer-a patient with schizophrenia on risperidone treatment. Ther. Drug Monit. 30(6), 748-751 (2008).
45. Yagcioglu AE, Ilhan BC, Goktas MT, Babaoglu MO, Uz E, Yazici MK. Agranulocytosis related to clozapine in monozygotic twins and association with allelic variants of multidrug resistance gene MDR1. J. Clin. Psychopharmacol. 31(2), 247-249 (2011).
46. Takao T, Tachikawa H, Kawanishi Y et al. Association of treatment-resistant schizophrenia with the G2677A/T and C3435T polymorphisms in the ATP-binding cassette subfamily B member 1 gene. Psychiatr. Genet. 16(2), 47-48 (2006). (Pubitemid 44481201)
47. El-Ela AA, Hartter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds-implications for pharmacokinetics of selected substrates. J. Pharm Pharmacol. 56(8), 967-975 (2004). (Pubitemid 39140051)
48. Schmitt U, El-Ela AA, Guo LJ et al. Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). J. Neural. Transm. 113(7), 787-801 (2006). (Pubitemid 43962774)
49. Härtter S, Huwel S, Lohmann T et al. How does the benzamide antipsychotic amisulpride get into the brain? An in vitro approach comparing amisulpride with clozapine. Neuropsychopharmacology 28(11), 1916-1922 (2003). (Pubitemid 37412102)
50. Wu J, Sha XY, Fang XL. Transport of aripiprazole across Caco-2 monolayer model. Yao Xue Xue Bao 44(2), 188-191 (2009).
51. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97(11), 2517-2524 (1996). (Pubitemid 26187339)
52. Henning U, Loffler S, Krieger K, Klimke A. Uptake of clozapine into HL-60 promyelocytic leukaemia cells. Pharmacopsychiatry 35(3), 90-95 (2002). (Pubitemid 34651914)
53. Maines LW, Antonetti DA, Wolpert EB, Smith CD. Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology 49(5), 610-617 (2005). (Pubitemid 41208282)
54. Huang L, Berry L, Ganga S et al. Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance. Drug Metab. Dispos. 38(2), 223-231 (2010).
55. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 71(2), 163-169 (2002). (Pubitemid 34595435)
56. Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl.) 187(4), 415-423 (2006). (Pubitemid 44200513)
57. Zhou YG, Li KY, Li HD. Effect of the novel antipsychotic drug perospirone on P-glycoprotein function and expression in Caco-2 cells. Eur. J. Clin. Pharmacol. 64(7), 697-703 (2008).
58. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br. J. Clin. Pharmacol. 61(1), 58-69 (2006) (Pubitemid 43381238)
59. Rahi M, Heikkinen T, Hartter S et al. Placental transfer of quetiapine in relation to P-glycoprotein activity. J. Psychopharmacol. 21(7), 751-756 (2007). (Pubitemid 47437915)
60. Faassen F, Vogel G, Spanings H, Vromans H. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int. J. Pharm. 263(1-2), 113-122 (2003). (Pubitemid 37087938)
61. Feng B, Mills JB, Davidson RE et al. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab. Dispos. 36(2), 268-275 (2008). (Pubitemid 351185738)
62. Cousein E, Barthelemy C, Poullain S et al. P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an in vitro Caco-2/TC7 model and an in vivo model. Prog. Neuropsychopharmacol Biol. Psychiatry 31(4), 878-886 (2007). (Pubitemid 46671480)
63. Mahar Doan KM, Humphreys JE, Webster LO et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 303(3), 1029-1037 (2002). (Pubitemid 35424386)
64. Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, DeVane CL. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology 32(4), 757-764 (2007). (Pubitemid 46426181)
65. Bachmeier CJ, Miller DW. A fluorometric screening assay for drug efflux transporter activity in the blood-brain barrier. Pharm. Res. 22(1), 113-121 (2005). (Pubitemid 40558153)
66. van de Vire W, Marquet RL, Stoter G, de Bruijn EA, Eggermont AM. In vivo model systems in P-glycoprotein-mediated multidrug resistance. Crit. Rev. Clin. Lab. Sci. 35(1), 1-57 (1998). (Pubitemid 28154244)
67. Chen C, Liu X, Smith BJ. Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development. Curr. Drug Metab. 4(4), 272-291 (2003). (Pubitemid 36958329)
68. Kirschbaum KM, Uhr M, Holthoewer D et al. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology 59(6), 474-479 (2010).
69. Wang JS, Zhu HJ, Donovan JL et al. Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophr. Res. 110(1-3), 90-94 (2009).
70. Dagenais C, Avdeef A, Tsinman O, Dudley A, Beliveau R. P-glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo PAMPA model. Eur. J. Pharm. Sci. 38(2), 121-137 (2009).
71. Doran A, Obach RS, Smith BJ et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos. 33(1), 165-174 (2005). (Pubitemid 40023528)
72. Wang JS, Taylor R, Ruan Y, Donovan JL, Markowitz JS, DeVane CL. Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology 29(3), 551-557 (2004). (Pubitemid 38365932)
73. Ejsing TB, Pedersen AD, Linnet K. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments. Hum. Psychopharmacol. 20(7), 493-500 (2005). (Pubitemid 41489461)
74. Kirschbaum KM, Henken S, Hiemke C, Schmitt U. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav. Brain Res. 188(2), 298-303 (2008).
75. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int. J. Neuropsychopharmacol. 7(4), 415-419 (2004). (Pubitemid 39648071)
76. Holthoewer D, Hiemke C, Schmitt U. Induction of drug transporters alters disposition of risperidone: a study in mice. Pharmaceutics 2(2), 258-274 (2010).
77. Pacchioni AM, Gabriele A, Donovan JL, Lindsay DeVane C, See RE. P-glycoprotein inhibition potentiates the behavioural and neurochemical actions of risperidone in rats. Int. J. Neuropsychopharmacol. 13(8), 1067-1077 (2010).
78. Nakagami T, Yasui-Furukori N, Saito M, Tateishi T, Kaneo S. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin. Pharmacol. Ther. 78(1), 43-51 (2005). (Pubitemid 40956930)
79. Kim KA, Park PW, Liu KH et al. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. J. Clin. Pharmacol. 48(1), 66-72 (2008).
80. De Leon J, Bork J. Risperidone and cytochrome P450 3A. J. Clin. Psychiatry. 58(10), 450 (1997).
81. Consoli G, Lastella M, Ciapparelli A et al. ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics 10(8), 1267-1276 (2009).
82. Jaquenoud Sirot E, Knezevic B, Morena GP et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J. Clin. Psychopharmacol. 29(4), 319-326 (2009).
83. Markowitz JS, DeVane CL, Malcolm RJ et al. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J. Clin. Pharmacol. 46(2), 164-171 (2006). (Pubitemid 43146447)
84. Skogh E, Sjodin I, Josefsson M, Dahl ML. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J. Clin. Psychopharmacol. 31(1), 4-9 (2011).
85. Ghotbi R, Mannheimer B, Aklillu E et al. Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure-an impact similar to male gender or smoking in schizophrenic patients. Eur. J. Clin. Pharmacol. 66(5), 465-474 (2010).
86. Yasui-Furukori N, Mihara K, Takahata T et al. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br. J. Clin. Pharmacol. 57(5), 569-575 (2004). (Pubitemid 38582176)
87. Xing Q, Gao R, Li H et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 7(7), 987-993 (2006). (Pubitemid 44644778)
88. Kastelic M, Koprivsek J, Plesnicar BK et al. MDR1 gene polymorphisms and response to acute risperidone treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(2), 387-392 (2010).
89. Yoo HD, Lee SN, Kang HA, Cho HY, Lee IK, Lee YB. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10. Br. J. Pharmacol. doi: 10.1111/j.1476-5381. 2011.01385.x (2011) (Epub ahead of print).
90. De Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 40(3), 93-102 (2007). (Pubitemid 46910379)
91. Gunes A, Spina E, Dahl ML, Scordo MG. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther. Drug Monit. 30(5), 628-633 (2008).
92. Jovanovic N, Bozina N, Lovric M, Medved V, Jakovljevic M, Peles AM. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naive patients with first-episode schizophrenia treated with risperidone. Eur. J. Clin. Pharmacol. 66(11), 1109-1117 (2010).
93. Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J. Clin. Pharmacol. 50(6), 659-666 (2010).
94. Mouaffak F, Kebir O, Picard V et al. Ultra-resistant schizophrenia is not associated with the multidrug-resistant transporter 1 (MDR1) gene rs1045642 variant. J. Clin. Psychopharmacol. 31(2), 236-238 (2011).
95. Lin YC, Ellingrod VL, Bishop JR, Miller DD. The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Ther. Drug Monit. 28(5), 668-672 (2006). (Pubitemid 44564067)
96. Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, Hotujac L. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J. Psychiatr. Res. 42(2), 89-97 (2008). (Pubitemid 350061252)
97. Correia CT, Almeida JP, Santos PE et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogen. J. 10(5), 418-430 (2010).
98. Kuzman MR, Medved V, Bozina N, Hotujac L, Sain I, Bilusic H. The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res. 160(3), 308-315 (2008).
99. De Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J. Clin. Psychopharmacol. 25(5), 448-456 (2005). (Pubitemid 41368367)
100. De Luca V, Souza RP, Viggiano E et al. MDR1 gene in tardive dyskinesia scale scores: comparison of strategies for quantitative trait haplotype analysis. Schizophr. Res. 110(1-3), 200-201 (2009).
101. Alenius M, Wadelius M, Dahl ML, Hartvig P, Lindstrom L, Hammarlund-Udenaes M. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J. Psychiatr. Res. 42(11), 884-893 (2008).
102. Yasui-Furukori N, Tsuchimine S, Saito M, Nakagami T, Sato Y, Kaneko S. Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry. 31(6), 1230-1234 (2007). (Pubitemid 47081309)
103. Sullivan PF. Spurious genetic associations. Biol. Psychiatry. 61(10), 1121-1126 (2007). (Pubitemid 46669468)
104. de Klerk OL, Willemsen AT, Bosker FJ et al. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11) C]verapamil as a probe for P-glycoprotein function. Psychiatry. Res. 183(2), 151-156 (2010).
105. Katoh M, Suzuyama N, Takeuchi T, Yoshitomi S, Asahi S, Yokoi T. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J. Pharm. Sci. 95(12), 2673-2683 (2006). (Pubitemid 46093174)
106. Suzuyama N, Katoh M, Takeuchi T et al. Species differences of inhibitory effects on P-glycoprotein-mediated drug transport. J. Pharm. Sci. 96(6), 1609-1618 (2007). (Pubitemid 46953775)
107. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2(1), 86-98 (2005). (Pubitemid 40128029)
108. Uehlinger C, Crettol S, Chassot P et al. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. J. Clin. Psychopharmacol. 27(3), 273-278 (2007). (Pubitemid 46763309)
109. De Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J. Clin. Psychiatry. 66(1), 15-27 (2005).
110. Kuzman MR, Medved V, Bozina N, Grubisin J, Jovanovic N, Sertic J. Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. Pharmacogen. J. 11(1), 35-44 (2011).
111. Mas S, Gassò P, Alvarez S, Parellada E, Bernardo M, Lafuente A. Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J. DOI: 10.1038/tpj.2010.91 (2010) (Epub ahead of print).